| Name | Title | Contact Details |
|---|---|---|
Pete Coman |
Chief Technology Officer | Profile |
Making advanced diagnostics and adoptive cell therapies more accessible by working from the bottom up via synthetic cells.
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company`s non-viral platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses its proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio`s manufacturing scale to hundreds of millions of doses to support their mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.
Flame Biosciences is a clinical stage company focused on the research, development and commercialization of transformative therapies for cancer and other inflammatory conditions.
Ibis Biosciences a Division of Abbott is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Omeros Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.